Theranos at a Crossroad: What's Next for the Startup?

The transcript discusses the challenges faced by Theranos, focusing on Sunny Balwani's controversial role, board member changes, and ongoing regulatory investigations. It highlights the company's lack of medical expertise and the need for data transparency. The future steps for Theranos include addressing compliance issues and providing substantial data to regain credibility.

How has the board composition at Theranos changed recently?

What are the expectations for the August 1st meeting regarding data publication?